Your browser doesn't support javascript.
loading
Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.
Tsao, Ming-Sound; Carbone, Michele; Galateau-Salle, Francoise; Moreira, Andre L; Nicholson, Andrew G; Roden, Anja C; Adjei, Alex A; Aubry, Marie-Christine; Fennell, Dean A; Gomez, Daniel; Harpole, David; Hesdorffer, Mary; Hirsch, Fred R; Liu, Geoffrey; Malik, Shakun; Nowak, Anna; Peikert, Tobias; Salgia, Ravi; Szlosarek, Peter; Taioli, Emanuela; Yang, Haining; Tsao, Anne; Mansfield, Aaron S.
Afiliação
  • Tsao MS; Department of Pathology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Carbone M; Thoracic Oncology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
  • Galateau-Salle F; MESOPATH, MESONAT, MESOBANK, Department of BioPathology, Centre Leon Berard, Lyon, France.
  • Moreira AL; Department of Pathology, New York University Langone Health, New York, New York.
  • Nicholson AG; Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom.
  • Roden AC; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Adjei AA; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
  • Aubry MC; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Fennell DA; Mesothelioma Research Programme, Leicester Cancer Research Centre, Leicester, United Kingdom.
  • Gomez D; Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Harpole D; Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, North Carolina.
  • Hesdorffer M; Mesothelioma Applied Research Foundation, Alexandria, Virginia.
  • Hirsch FR; Mount Sinai Health System, Center for Thoracic Oncology/Tisch Cancer Center, New York, New York.
  • Liu G; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Malik S; Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Nowak A; National Centre for Asbestos Related Disease, University of Western Australia, Nedlands, Western Australia, Australia.
  • Peikert T; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
  • Salgia R; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California.
  • Szlosarek P; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Taioli E; Department of Epidemiology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Yang H; Thoracic Oncology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
  • Tsao A; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Mansfield AS; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: Mansfield.aaron@mayo.edu.
J Thorac Oncol ; 14(10): 1704-1717, 2019 10.
Article em En | MEDLINE | ID: mdl-31260832
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Biomarcadores Tumorais / Ensaios Clínicos como Assunto / Mesotelioma Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Biomarcadores Tumorais / Ensaios Clínicos como Assunto / Mesotelioma Idioma: En Ano de publicação: 2019 Tipo de documento: Article